Loading

SCIENCE

  • by Justin Strekal, NORML Political Director November 2, 2017

    IMG_2898 copyIn a new poll of US service veterans conducted by The American Legion and presented today on Capitol Hill, one in five veterans self-reported using marijuana to alleviate a medical or physical condition.

    Flanked by lawmakers including Reps Tim Walz, Mark Takano, Julia Brownley, and Matt Gaetz, veterans presented their own personal stories of the efficacy of marijuana as a therapeutic treatment for a litany of conditions.

    Other notable data points revealed by the survey:

    •  81% of veterans support federally-legal treatment
    • 60% of respondents do not live in states where medical cannabis is legal
    • 40% of respondents live in states where medical cannabis is legal
    • And the partisan divide is nearly non-existent:
      • 88% of self-identified conservative respondents support federally legalized medical
        cannabis
      • 90% of self-identified liberal respondents support federally legalized medical
        cannabis
      • 70% of self-identified non-partisan respondents support federally legalized medical
        cannabis

    My favorite data point from their poll: 100% of respondents aged 18-30 support federally legalized medical cannabis.

    You can support the same legislation that the American Legion supports, the Veterans Equal Access Act, which would allow those who have served our country to discuss and be recommended medical marijuana in the states that have implemented programs by CLICKING HERE. 

  • by Paul Armentano, NORML Deputy Director November 1, 2017

    GovChristieDespite the growing body of scientific evidence showing that cannabis access is associated with reductions in opioid use and mortality, the Chairman of the White House’s Commission on Combating Drug Addiction and the Opioid Crisis today called upon the President to reject any efforts to acknowledge marijuana’s promising role in mitigating opioid abuse and dependency.

    In a letter sent today to President Donald Trump by New Jersey Gov. Chris Christie, Chairman of the Committee, he writes:

    “The Commission acknowledges that there is an active movement to promote the use of
    marijuana as an alternative medication for chronic pain and as a treatment for opioid addiction. … There is a lack of sophisticated outcome data on dose, potency, and abuse potential for marijuana. This mirrors the lack of data in the 1990’s and early 2000’s when opioid prescribing multiplied across health care settings and led to the current
    epidemic of abuse, misuse and addiction. The Commission urges that the same mistake is not made with the uninformed rush to put another drug legally on the market in the midst of an overdose epidemic.”

    President Trump established the Commission in May via an executive order. Members of the Commission issued their policy recommendations today.

    In recent months, dozens of peer-reviewed studies have concluded that legal cannabis access is associated with reduced rates of opioid use, spending, abuse, hospitalization, and mortality. Summaries and links to these studies are available here.

    Despite over 10,000 advocates communicating this information to the Commission, members of the committee have chosen to disregard it. Moreover, Gov. Christie opines in today’s letter that cannabis exposure increases the likelihood that one will become opioid dependent — an allegation that was recently rejected by the National Academy of Sciences, which, in a January 2017 review of some 10,000 peer-reviewed studies, failed to identify even one “good or fair-quality systematic review that reported on the association between cannabis use and the initiation of use of opioids.”

    NORML thanks the thousands of you who took the time to try to inform and educate this Commission and regrets that its members continue to place political ideology above the health and safety of American lives.

  • by Paul Armentano, NORML Deputy Director October 30, 2017

    medical_mj_shelfMembers of the US House Committee on Veteran’s Affairs are demanding the Department of Veterans Affairs facilitate protocols to assess the efficacy of medical cannabis in veterans suffering from chronic pain and post-traumatic stress.

    Minnesota Democrat Tim Walz, along with nine other Democrat members of the Committee, authored an October 26, 2017 letter to VA Secretary David Shulkin stating: “[The] VA is uniquely situated to pursue research on the impact of medical marijuana on veterans suffering from chronic pain and PTSD given its access to world class researchers, the population it serves, and its history of overseeing and producing research resulting in cutting-edge medical treatments. … VA’s pursuit of research into the impact of medical marijuana on the treatment of veterans diagnosed with PTSD who are also experiencing chronic pain is integral to the advancement of health care for veterans and the nation. We ask VA to respond … with a commitment to the development of VHA-led research into this issue.”

    In September, representatives from The American Legion addressed a separate letter to VA Secretary Shulkin encouraging the VA assist in an ongoing, FDA-approved clinical trial assessing the safety and efficacy of various strains of cannabis in veterans with PTSD. To date, the VA has refused to assist in patient recruitment for the trial. The VA has yet to publicly respond to the Legion’s letter.

    Survey data finds that military veterans report using cannabis therapeutically at rates far higher than the do those in the general population, and that many are already using it as an alternative to conventional medications in the treatment of pain and post-traumatic stress.

  • by NORML October 23, 2017

    HumboldtOne of NORML’s primary missions is to move public opinion sufficiently to legalize the responsible use of marijuana by adults. One of the ways we successfully achieve this goal is by debunking marijuana myths and half-truths via the publication of timely op-eds in online and print media. Since the mainstream media seldom casts a critical eye toward many of the more over-the-top claims about cannabis, we take it upon ourselves to set the record straight.

    The majority of NORML’s rebuttals are penned by Deputy Director Paul Armentano. In the past few weeks, he has published numerous op-eds rebuking a litany of popular, but altogether specious claims about the cannabis plant – including the contentions that cannabis consumption is linked to poor health outcomes, problems with regulations, and the effects of opioid abuse, hospitalizations, and fatalities in the states that have robust medical marijuana programs.

    Below are links to a sampling of his recent columns:

    Trump’s opioid agency fails to cite marijuana’s benefits, despite mounting evidence
    The Hill, October 23, 2017

    This is how legal cannabis is improving public health
    National Memo, October 22, 2017

    RMHIDTA’s marijuana reports are nothing but propaganda
    Denver Westword, October 21, 2017

    Marijuana is now a driving engine of the American economy
    Alternet, September 28, 2017

    When will our govt stop ignoring that marijuana is a major regulation success story
    Alternet, September 19, 2017

    Blowing up the big marijuana IQ myth — The science points to zero effect on your smarts
    The National Memo, August 7, 2017

    For a broader sampling of NORML-centric columns and media hits, please visit NORML’s ‘In the Media’ archive here.

    If you see the importance of NORML’s educational and media outreach efforts, please feel free to show your support by making a contribution here.

  • by Paul Armentano, NORML Deputy Director October 20, 2017

    Medical marijuanaAdults with a history of cannabis use are less likely to suffer from non-alcoholic fatty liver disease (NAFLD) than are those who have not used the substance, according to data published online in the journal PLoS One. Non-alcoholic fatty liver disease is the most prevalent form of liver disease, affecting an estimated 80 to 100 million people in the United States.

    An international team of researchers from Stanford University in California and the Seoul National University College of Medicine in South Korea evaluated the association between marijuana and NAFLD in a nationally representative sample of over 22,000 adults. Researchers reported that cannabis use independently predicted a lower risk of suspected NAFLD in a dose-dependent manner.

    “Active marijuana use provided a protective effect against NAFLD independent of known metabolic risk factors,” authors determined. “[W]e conclude that current marijuana use may favorably impact the pathogenesis of NAFLD in US adults.”

    The findings are similar to those of a prior study published in the same journal in May. In that study, authors reported that frequent consumers of cannabis were 52 percent less likely to be diagnosed with NAFLD as compared to non-users, while occasional consumers were 15 percent less likely to suffer from the disease.

    Separate data published online earlier this month in the Journal of Viral Hepatitis also concluded that daily cannabis use is independently associated with a reduced prevalence of fatty liver disease in patients co-infected with HIV and hepatitis C.

    Full text of the study, “Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States,” appears online here.

Page 1 of 8612345...102030...Last »